ClinicalTrials.gg
CompletedNCT04209114Updated Jun 27, 2024Results posted

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

A Phase 3 interventional study of Nivolumab and Radical cystectomy (RC) in Bladder Cancer, Bladder Tumor and Muscle-Invasive Bladder Cancer, sponsored by Bristol-Myers Squibb. Completed at 116 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.

Enrollment
9th of 25
114 · median 76
Started
2020
with 2 others
Phase 3
4 of 25
none open now
Registered
19th of 25
by date
Lead sponsor
5 of 25
Bristol-Myers Squibb

Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 19th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing nivolumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to see if treatment with nivolumab plus bempegaldesleukin or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with high-risk urothelial cancer, including muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy.

03

Conditions studied

  • Bladder Cancer
  • Bladder Tumor
  • Muscle-Invasive Bladder Cancer

Keywords

  • immunotherapy
  • NKTR-214
  • nivolumab
  • bempeg
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Urothelial carcinoma (UC) of the bladder, clinical stage T2-T4aN0, M0 or T1-T4aN1, M0, diagnosed at transurethral resection of bladder tumor (TURBT)
  • Must be deemed eligible for Radical Cystectomy (RC) by urologist, and must agree to undergo RC. For arms A and B, participants must agree to undergo RC after completion of therapy.
  • (ECOG) performance status 0 or 1
  • Cisplatin-ineligible participants will be defined by any one of the following criteria:

    i) Impaired renal function ( [GFR] ≥ 30 but \< 60 mL/min) ii) GFR should be assessed by direct measurement (ie, ) or, if not available, by calculation from serum/plasma creatinine (Cockcroft-Gault formula) iii) (CTCAE) version 5, ≥ Grade 2 hearing loss (assessed per local SOC).

iv) CTCAE version 5, ≥ Grade 2 peripheral neuropathy.

  • Documented (LVEF) more than 45%

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of ≥ N2 or bladder cancer
  • Prior systemic therapy, radiation therapy, or surgery for bladder cancer other than TURBT or is not permitted. Prior Bacillus Calmette-Guerin (BCG) or other intravesicular treatment of non-muscle invasive bladder cancer (NMIBC) is permitted if completed at least 6 weeks prior to initiating study treatment.
  • Evidence of urothelial carcinoma (UC) in upper urinary tracts (ureters or renal pelvis) or history of previous MIBC
  • History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior venous or non-CVA(cerebrovascular accident)/ (Transient ischemic attack) arterial thromboembolic event
  • Known cardiovascular history, including unstable or deteriorating cardiac disease within the previous 12 months (including unstable angina or myocardial infarction, congestive heart failure or uncontrolled clinically significant arrhythmias)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Arm A: Combination Therapy

    Neoadjuvant (pre-surgical treatment) nivolumab + bempeg, followed by radical cystectomy (RC), followed by adjuvant (post-surgical treatment) nivolumab + bempeg

    Biological: Nivolumab · Procedure: Radical cystectomy (RC) · Biological: Bempegaldesleukin

  • Experimental
    Arm B: Monotherapy

    Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab

    Biological: Nivolumab · Procedure: Radical cystectomy (RC)

  • Other
    Arm C: Standard-of-care

    RC alone, without neoadjuvant or adjuvant therapy

    Procedure: Radical cystectomy (RC)

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • ProcedureRadical cystectomy (RC)

    Surgical removal of the bladder

  • Specified dose on specified days

    Also known as: BMS-986321, NKTR-214, Bempeg

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care

    Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.

    Time frame: From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)

  2. Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care

    Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).

    Time frame: From randomization up to first EFS event (up to approximately 30 months)

Secondary outcomes

  1. Pathologic Complete Response (pCR) Rate - Nivolumab Compared to Standard of Care

    Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.

    Time frame: From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)

  2. Event Free Survival (EFS) - Nivolumab Compared to Standard of Care

    Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).

    Time frame: From randomization up to first EFS event (up to approximately 30 months)

  3. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive. OS was not calculated for Arm A and Arm B because the number of events did not meet the threshold due to early study termination. In lieu of OS, time to death is reported as a Post-Hoc endpoint.

    Time frame: From randomization to study completion, up to approximately 40 months

  4. The Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: from first dose to 100 days following last dose (up to approximately 20 months)

  5. The Number of Participants Experiencing Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: from first dose to 100 days following last dose (up to approximately 20 months)

  6. The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: from first dose to 100 days following last dose (up to approximately 20 months)

  7. The Number of Participants Experiencing Immune-Mediated Adverse Events (IMAEs)

    IMAEs are specific AEs that include pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine (adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-mediated events by investigator that meet the definition summarized below: * those occurring within 100 days of the last dose, * regardless of causality, * treated with immune-modulating medication (of note, endocrine AEs such as adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis are considered IMAEs regardless of immune-modulating medication use, since endocrine drug reactions are often managed without immune-modulating medication). * with no clear alternate etiology based on investigator assessment, or with an immune-mediated component.

    Time frame: from first dose to 100 days following last dose (up to approximately 20 months)

  8. Worst Grade Clinical Laboratory Values

    Clinical laboratory values by worst CTC grade are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose to 100 days following last dose (up to approximately 20 months)

07

Results

Posted Jun 27, 2024
Limitations and caveats
BMS and Nektar Therapeutics jointly decided to terminate the clinical development program for bempegaldesleukin (NKTR-214) in combination with nivolumab. Discontinued survival follow-up and the stopping of submission of local labs to vendors, imaging to the BICR vendor, and PROs have resulted in confounded and incomplete trial results.

Participant flow

Pre-Treatment Phase
Participant flow — Pre-Treatment Phase
MilestoneArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
Started373740
Completed373732
Not completed008
Withdrew: Completed without radical cystectomy005
Withdrew: Other reasons001
Withdrew: Death001
Withdrew: Participant withdrew consent001
Treatment Phase
Participant flow — Treatment Phase
MilestoneArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
Started373732
Completed151332
Not completed22240
Withdrew: Other reasons530
Withdrew: Lost to follow-up100
Withdrew: Participant withdrew consent100
Withdrew: Adverse event unrelated to study drug150
Withdrew: Death410
Withdrew: Study drug toxicity460
Withdrew: Disease progression690

Outcome measures

PrimaryPathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care

Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.

Time frame:
From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)
Reported as:
Number · Percentage of participants
Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care
Percentage of participantsArm A: Nivolumab + BempegaldesleukinArm C: Standard of Care
Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care10.8 (3.0 to 25.4)2.5 (0.1 to 13.2)
PrimaryEvent Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care

Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).

Time frame:
From randomization up to first EFS event (up to approximately 30 months)
Reported as:
Median · Months
Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care
MonthsArm A: Nivolumab + BempegaldesleukinArm C: Standard of Care
Event Free Survival (EFS) - Nivolumab + Bempegaldesleukin Compared to Standard of Care22.11 (8.21 to NA)15.18 (11.63 to NA)
SecondaryPathologic Complete Response (pCR) Rate - Nivolumab Compared to Standard of Care

Pathologic Complete Response (pCR) is defined as the percentage of randomized participants with absence of any cancer in pathology specimens after radical cystectomy, based on blinded independent pathology review (BIPR). Participants who do not undertake surgery will be counted as non-pCR.

Time frame:
From time of radical cystectomy up to 100 days after last treatment (up to approximately 17 months)
Reported as:
Number · Percentage of participants
Pathologic Complete Response (pCR) Rate - Nivolumab Compared to Standard of Care
Percentage of participantsArm B: NivolumabArm C: Standard of Care
Pathologic Complete Response (pCR) Rate - Nivolumab Compared to Standard of Care10.8 (3.0 to 25.4)2.5 (0.1 to 13.2)
SecondaryEvent Free Survival (EFS) - Nivolumab Compared to Standard of Care

Event Free Survival (EFS) is defined as the time from randomization to any of the following events: progression of disease that precludes surgery, local or distant recurrence based on blinded independent committee review (BICR) assessments, or death due to any cause. Participants who did not have an EFS event will be censored on the date of their last evaluable tumor assessment (imaging or biopsy) or at the date of radical surgery whichever occur last. Participants who did not have any baseline tumor assessments (imaging or biopsy) and did not undergo radical cystectomy for other reason than worsening/progression of disease will be censored on their date of randomization. Participants who did not have any on study tumor assessments (imaging or biopsy) and did not die will be censored on their date of radical cystectomy (or randomization date if no radical cystectomy performed).

Time frame:
From randomization up to first EFS event (up to approximately 30 months)
Reported as:
Median · Months
Event Free Survival (EFS) - Nivolumab Compared to Standard of Care
MonthsArm B: NivolumabArm C: Standard of Care
Event Free Survival (EFS) - Nivolumab Compared to Standard of CareNA (10.84 to NA)15.18 (11.63 to NA)
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive. OS was not calculated for Arm A and Arm B because the number of events did not meet the threshold due to early study termination. In lieu of OS, time to death is reported as a Post-Hoc endpoint.

Time frame:
From randomization to study completion, up to approximately 40 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
Overall Survival (OS)NA (NA to NA)NA (NA to NA)23.23 (14.36 to NA)
Post-hocTime to Death

The amount of time in months from when participants were randomized until death. Survival was reported as time to death instead of overall survival by Kaplan-Meier analysis due to the small number of events at the time of early study completion.

Time frame:
From randomization to study completion, up to approximately 40 months
Reported as:
Median · Months
Time to Death
MonthsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
Time to Death6.77 (3.2 to 18.4)9.43 (1.8 to 20.1)8.49 (1.6 to 23.2)
SecondaryThe Number of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
from first dose to 100 days following last dose (up to approximately 20 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs)
ParticipantsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
The Number of Participants Experiencing Adverse Events (AEs)343619
SecondaryThe Number of Participants Experiencing Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
from first dose to 100 days following last dose (up to approximately 20 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
The Number of Participants Experiencing Serious Adverse Events (SAEs)151814
SecondaryThe Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
from first dose to 100 days following last dose (up to approximately 20 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation880
SecondaryThe Number of Participants Experiencing Immune-Mediated Adverse Events (IMAEs)

IMAEs are specific AEs that include pneumonitis, diarrhea/colitis, hepatitis, nephritis/renal dysfunction, rash, endocrine (adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis), and other specific events, considered as potential immune-mediated events by investigator that meet the definition summarized below: * those occurring within 100 days of the last dose, * regardless of causality, * treated with immune-modulating medication (of note, endocrine AEs such as adrenal insufficiency, hypothyroidism/thyroiditis, hyperthyroidism, diabetes mellitus, and hypophysitis are considered IMAEs regardless of immune-modulating medication use, since endocrine drug reactions are often managed without immune-modulating medication). * with no clear alternate etiology based on investigator assessment, or with an immune-mediated component.

Time frame:
from first dose to 100 days following last dose (up to approximately 20 months)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Immune-Mediated Adverse Events (IMAEs)
ParticipantsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
The Number of Participants Experiencing Immune-Mediated Adverse Events (IMAEs)10100
SecondaryWorst Grade Clinical Laboratory Values

Clinical laboratory values by worst CTC grade are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose to 100 days following last dose (up to approximately 20 months)
Reported as:
Count of participants · Participants
Worst Grade Clinical Laboratory Values
ParticipantsArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
Hemoglobin — Grade 0550
Hemoglobin — Grade 123232
Hemoglobin — Grade 2783
Hemoglobin — Grade 3111
Hemoglobin — Grade 4000
Hemoglobin — Not Reported1026
Platelet Count — Grade 035345
Platelet Count — Grade 1131
Platelet Count — Grade 2000
Platelet Count — Grade 3000
Platelet Count — Grade 4000
Platelet Count — Not Reported1026
Leukocytes, Local Lab — Grade 033356
Leukocytes, Local Lab — Grade 1220
Leukocytes, Local Lab — Grade 2000
Leukocytes, Local Lab — Grade 3100
Leukocytes, Local Lab — Grade 4000
Leukocytes, Local Lab — Not Reported1026
Lymphocytes (Absolute), Local Lab — Grade 023120
Lymphocytes (Absolute), Local Lab — Grade 1460
Lymphocytes (Absolute), Local Lab — Grade 2060
Lymphocytes (Absolute), Local Lab — Grade 3320
Lymphocytes (Absolute), Local Lab — Grade 4000
Lymphocytes (Absolute), Local Lab — Not Reported71132
Absolute Neutrophil Count — Grade 031360
Absolute Neutrophil Count — Grade 1410
Absolute Neutrophil Count — Grade 2000
Absolute Neutrophil Count — Grade 3000
Absolute Neutrophil Count — Grade 4100
Absolute Neutrophil Count — Not Reported1032
Alkaline Phosphate, Local Lab — Grade 024302
Alkaline Phosphate, Local Lab — Grade 11070
Alkaline Phosphate, Local Lab — Grade 2200
Alkaline Phosphate, Local Lab — Grade 3000
Alkaline Phosphate, Local Lab — Grade 4000
Alkaline Phosphate, Local Lab — Not Reported1030
Aspartate Aminotransferase, Local Lab — Grade 031302
Aspartate Aminotransferase, Local Lab — Grade 1560
Aspartate Aminotransferase, Local Lab — Grade 2010
Aspartate Aminotransferase, Local Lab — Grade 3000
Aspartate Aminotransferase, Local Lab — Grade 4000
Aspartate Aminotransferase, Local Lab — Not Reported1030
Alanine Aminotransferase, Local Lab — Grade 026302
Alanine Aminotransferase, Local Lab — Grade 11070
Alanine Aminotransferase, Local Lab — Grade 2000
Alanine Aminotransferase, Local Lab — Grade 3000
Alanine Aminotransferase, Local Lab — Grade 4000
Alanine Aminotransferase, Local Lab — Not Reported1030
Total Bilirubin, Local Lab — Grade 033352
Total Bilirubin, Local Lab — Grade 1220
Total Bilirubin, Local Lab — Grade 2100
Total Bilirubin, Local Lab — Grade 3000
Total Bilirubin, Local Lab — Grade 4000
Total Bilirubin, Local Lab — Not Reported1030
Creatinine, Local Lab — Grade 011135
Creatinine, Local Lab — Grade 110141
Creatinine, Local Lab — Grade 21290
Creatinine, Local Lab — Grade 3310
Creatinine, Local Lab — Grade 4000
Creatinine, Local Lab — Not Reported1026
Hypernatremia — Grade 034366
Hypernatremia — Grade 1210
Hypernatremia — Grade 2000
Hypernatremia — Grade 3000
Hypernatremia — Grade 4000
Hypernatremia — Not Reported1026
Hyponatremia — Grade 024295
Hyponatremia — Grade 11271
Hyponatremia — Grade 2000
Hyponatremia — Grade 3010
Hyponatremia — Grade 4000
Hyponatremia — Not Reported1026
Hyperkalemia — Grade 024256
Hyperkalemia — Grade 1790
Hyperkalemia — Grade 2430
Hyperkalemia — Grade 3100
Hyperkalemia — Grade 4000
Hyperkalemia — Not Reported1026
Hypokalemia — Grade 024256
Hypokalemia — Grade 1790
Hypokalemia — Grade 2430
Hypokalemia — Grade 3100
Hypokalemia — Grade 4000
Hypokalemia — Not Reported1026
Hypercalcemia — Grade 033344
Hypercalcemia — Grade 1330
Hypercalcemia — Grade 2000
Hypercalcemia — Grade 3000
Hypercalcemia — Grade 4000
Hypercalcemia — Not Reported1028
Hypocalcemia — Grade 029280
Hypocalcemia — Grade 1673
Hypocalcemia — Grade 2111
Hypocalcemia — Grade 3010
Hypocalcemia — Grade 4000
Hypocalcemia — Not Reported1028

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 40 months). Serious adverse events (SAEs) and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 20 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivolumab + Bempegaldesleukin8/37 (21.6%)16/37 (43.2%)32/37 (86.5%)
Arm B: Nivolumab6/37 (16.2%)22/37 (59.5%)29/37 (78.4%)
Arm C: Standard of Care12/40 (30%)15/32 (46.9%)18/32 (56.3%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
SepsisInfections and infestations2/371/374/32
Urinary tract infectionInfections and infestations4/371/373/32
Acute myocardial infarctionCardiac disorders0/373/370/32
Intestinal obstructionGastrointestinal disorders0/373/370/32
PyelonephritisInfections and infestations0/373/370/32
Acute kidney injuryRenal and urinary disorders2/373/370/32
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/370/372/32
Atrial fibrillationCardiac disorders2/370/370/32
Cardiac arrestCardiac disorders0/371/371/32
ConstipationGastrointestinal disorders0/370/371/32
Most frequent other events
Showing 10 of 64
Most frequent other events
EventArm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of Care
PruritusSkin and subcutaneous tissue disorders13/376/370/32
PyrexiaGeneral disorders10/373/374/32
AstheniaGeneral disorders9/375/371/32
DiarrhoeaGastrointestinal disorders8/373/370/32
FatigueGeneral disorders8/376/373/32
AnaemiaBlood and lymphatic system disorders4/377/372/32
ConstipationGastrointestinal disorders4/377/374/32
Urinary tract infectionInfections and infestations5/377/372/32
Weight decreasedInvestigations4/377/372/32
HypertensionVascular disorders1/376/370/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of CareTotal
Median73.0 ± 8.872.0 ± 7.574.5 ± 8.474.0 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of CareTotal
Female67922
Male31303192
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Nivolumab + BempegaldesleukinArm B: NivolumabArm C: Standard of CareTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White363536107
More than one race0000
Unknown or Not Reported1236
08

Study locations

116 sites
  • Local Institution - 0080
    Gilbert, Arizona 85234, United States
  • Local Institution - 0136
    Tucson, Arizona 85724, United States
  • Local Institution - 0029
    La Jolla, California 92092-0698, United States
  • Local Institution - 0015
    Orange, California 92868, United States
  • Local Institution - 0002
    Iowa City, Iowa 52242, United States
  • Local Institution
    Rochester, Minnesota 55905, United States
  • Local Institution - 0006
    New Brunswick, New Jersey 08903, United States
  • Local Institution - 0009
    Bronx, New York 10461, United States
  • Local Institution - 0004
    Buffalo, New York 14263, United States
  • Local Institution - 0005
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0007
    Charleston, South Carolina 29425, United States
  • Local Institution - 0139
    Houston, Texas 77030, United States
  • Local Institution - 0023
    Temple, Texas 76508, United States
  • Local Institution - 0122
    Gig Harbor, Washington 98332, United States
  • Local Institution - 0102
    Seattle, Washington 98109, United States
  • Local Institution - 0096
    Capital Federal, Buenos Aires 1419, Argentina
  • Local Institution - 0028
    Ciudad Autónoma De Buenos Aires, Buenos Aires 1426, Argentina
  • Local Institution - 0124
    La Plata, Buenos Aires 1900, Argentina
  • Local Institution - 0027
    Capital Federal, Distrito Federal C1280AEB, Argentina
  • Local Institution - 0174
    Rosario, Santa FE S2000DTC, Argentina
  • Local Institution - 0097
    Cordoba, 5000, Argentina
  • Local Institution - 0137
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0158
    Ballarat, Victoria 3350, Australia
  • Local Institution - 0157
    Fitzroy, Victoria 3065, Australia
  • Local Institution - 0011
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0013
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0148
    Graz, 8036, Austria
  • Local Institution - 0150
    Vienna, 1160, Austria
  • Local Institution - 0123
    Wien, 1090, Austria
  • Local Institution - 0083
    Wilrijk, Antwerpen 2610, Belgium
  • Local Institution - 0101
    Brussel, Brussels 1090, Belgium
  • Local Institution - 0098
    Edegem, 2650, Belgium
  • Local Institution - 0068
    Gent, 9000, Belgium
  • Local Institution - 0100
    Liège, 4000, Belgium
  • Local Institution - 0177
    Porto Alegre, RIO Grande DO SUL 90560-030, Brazil
  • Local Institution - 0039
    Porto Alegre, RIO Grande DO SUL 91350-200, Brazil
  • Local Institution - 0176
    Barretos, SAO Paulo 14784400, Brazil
  • Local Institution - 0037
    Jau, Sao Paulo 17210-120, Brazil
  • Local Institution - 0038
    Sao Paulo, São Paulo 01509-010, Brazil
  • Local Institution - 0041
    Rio de Janeiro, 20231-050, Brazil
  • Local Institution - 0040
    Sao Paulo, 01246-000, Brazil
  • Local Institution - 0082
    Oshawa, Ontario L1G 2B9, Canada
  • Local Institution - 0036
    Sherbrooke, Quebec JiH 5N4, Canada
  • Local Institution - 0018
    Quebec, G1R3S1, Canada
  • Local Institution - 0204
    Chongqing, Chongqing 400016, China
  • Local Institution
    Xiamen, Fujian 361003, China
  • Local Institution
    Zhengzhou, Henan 450000, China
  • Local Institution
    Wuhan, Hubei 430022, China
  • Local Institution
    Changsha, Hunan 410031, China
  • Local Institution
    Taiyuan, Shan1xi, China
  • Local Institution
    Jinan, Shandong 250117, China
  • Local Institution - 0022
    Olomouc, 77900, Czechia
  • Local Institution - 0020
    Praha 5, 150 06, Czechia
  • Local Institution - 0021
    Praha, 14059, Czechia
  • Local Institution - 0077
    Avignon Cedex 9, 84918, France
  • Local Institution - 0091
    Bordeaux, 33075, France
  • Local Institution - 0151
    Clermont-Ferrand, 63011, France
  • Local Institution - 0059
    La Roche-sur-Yon, 85000, France
  • Local Institution - 0071
    Lyon, 69008, France
  • Local Institution - 0057
    Marseille Cedex 9, 13273, France
  • Local Institution - 0075
    Montpellier, 34298, France
  • Local Institution - 0070
    Nice, 06189, France
  • Local Institution - 0062
    Paris, 75014, France
  • Local Institution - 0060
    Paris, 75908, France
  • Local Institution - 0064
    Quimper, 29000, France
  • Local Institution - 0161
    Reims, 51726, France
  • Local Institution - 0058
    Strasbourg, 67200, France
  • Local Institution - 0056
    Suresnes, 92151, France
  • Local Institution - 0074
    Tours, 37000, France
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Local Institution - 0117
    Duesseldorf, 40225, Germany
  • Local Institution - 0119
    Erlangen, 91054, Germany
  • Local Institution - 0050
    Essen, 45147, Germany
  • Local Institution - 0052
    Hamburg, 20246, Germany
  • Local Institution - 0051
    Hamburg, 22763, Germany
  • Local Institution - 0049
    Herne, 44625, Germany
  • Local Institution - 0045
    Jena, 07747, Germany
  • Local Institution - 0053
    Luebeck, 23538, Germany
  • Local Institution - 0113
    Muenster, 48149, Germany
  • Local Institution - 0048
    Nuernberg, 90419, Germany
  • Local Institution - 0046
    Tuebingen, 72076, Germany
  • Local Institution - 0178
    Athens, 11528, Greece
  • Local Institution - 0088
    Athens, 15125, Greece
  • Local Institution - 0033
    Chaidari, 12462, Greece
  • Local Institution - 0035
    Thessaloniki, 56429, Greece
  • Local Institution - 0129
    Haifa, 31096, Israel
  • Local Institution - 0131
    Tel Aviv, 6423906, Israel
  • Local Institution - 0130
    Tel Hashomer, 52621, Israel
  • Local Institution - 0149
    Firenze, 50134, Italy
  • Local Institution - 0162
    Milano, 20132, Italy
  • Local Institution - 0025
    Milano, 20133, Italy
  • Local Institution
    Pavia, 27100, Italy
  • Local Institution - 0026
    Pisa, 56126, Italy
  • Local Institution - 0065
    Roma, 00168, Italy
  • Local Institution - 0044
    Rozzano, 20089, Italy
  • Local Institution - 0154
    La Paz, BAJA Californa SUR 23040, Mexico
  • Local Institution - 0132
    Ciudad de Mexico, Distrito Federal 06100, Mexico
  • Local Institution - 0160
    Mexico, Distrito Federal 06700, Mexico
  • Local Institution - 0133
    Monterrey, Nuevo LEON 64460, Mexico
  • Local Institution - 0069
    Amsterdam, 1066 CX, Netherlands

Showing the first 100 of 116 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jun 2023, 40 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 40 months is below that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2019
First posted
Dec 23, 2019
StartActual
Feb 5, 2020
Primary completionActual
Jun 7, 2023
CompletionActual
Jun 7, 2023
Results first posted
Jun 27, 2024
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04209114
Collaborators
Nektar Therapeutics
Responsible party
Sponsor
First posted
Dec 23, 2019
Start date
Feb 5, 2020
Primary completion
Jun 7, 2023
Completion
Jun 7, 2023
Results posted
Jun 27, 2024
Last update
Jun 27, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Bempegaldesleukin

Start the discussion